Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Dec 2024 value amounting to $61.0 million.

  • Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) rose 8.23% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year increase of 8.23%. This contributed to the annual value of $61.0 million for FY2024, which is 5.76% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $61.0 million for FY2024, which was up 5.76% from $57.7 million recorded in FY2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $61.0 million during FY2024, and registered a low of $49.6 million during FY2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $57.7 million in 2023 and averaged $56.9 million.
  • Data for Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY grew of 10.65% (in 2023) over the last 5 years.
  • Over the past 4 years, Rhythm Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $49.6 million in 2021, then increased by 5.08% to $52.1 million in 2022, then increased by 10.65% to $57.7 million in 2023, then climbed by 5.76% to $61.0 million in 2024.